NCT05160337 Validation of the Stability of Diagnostic Biomarkers on Healthy Volunteers
| NCT ID | NCT05160337 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Firalis SA |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06-18 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-06-18 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stability studies on the peripheral biomarkers (lncRNAs, sncRNAs, mRNAs, proteins, lipids/metabolites) measured by Firalis IVD test candidates and effect of gender, age, nutrition on their expression level
Eligibility Criteria
Inclusion Criteria: * Participants who sign the informed consent forms for sample collection and data collection both anonymized and reported in CRF. * Able to comply with all study procedures. * Healthy Volunteers having no apparent disease. * Adults, both genders, aged 18-85 years. * Participants with no apparent motor or mental health abnormality. * Participants having no major disabling mental or physical disability that would require hospitalization. * Body weight above 50 kg if male, above 40 kg if female. Exclusion Criteria: * Any subject who did not sign the Informed Consent form. * Any subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development. * Any subject in the exclusion period of a previous study according to applicable regulations. * Any subject who cannot be contacted in case of emergency. * Any subject who is the Investigator or any sub-investigator, research assistant, study coordinator, or other staff thereof, directly involved in the conduct of the protocol. * Any subject with a disease that, in the judgement of the investigator, would interfere with the conduct of study or harm the safety of volunteer. * Subjects with disabling disease or abnormal health status are excluded. * Subjects aged below 18 years and older than 85 years are excluded. * Pregnant, parturient and nursing women are excluded. * Subjects deprived of their liberty by a judicial or administrative decision, protected adults and vulnerable persons are excluded. * Subjects who are under legal protection or who are unable to express their consent are not included. * Any subject who reports in the questionnaire of the screening period having one of the following diseases is excluded: * Any psychiatric or neurodegenerative disease or neurologic disorder. * Hypertension. * Any cardiovascular disease. * Any chronic inflammatory disease such as rheumatoid arthritis. * Any cancer. * Frequent headaches and/or migraine, recurrent nausea and/or vomiting. * Any subject who did a blood donation, any volume, within 2 months before inclusion. * Any subject who reports in the questionnaire of the screening period having medication(s) for one or more of the above diseases is excluded. * Drug or alcohol abuse or smoking more than 10 cigarettes or equivalent. * Subjects with no apparent disease and symptoms, but with unknown Covid-19 positivity are not excluded.
Contact & Investigator
Pierre Rohrlich, MD,Phd
PRINCIPAL INVESTIGATOR
Firalis SA
Frequently Asked Questions
Who can join the NCT05160337 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05160337 currently recruiting?
Yes, NCT05160337 is actively recruiting participants. Contact the research team at clinical@firalis.com for enrollment information.
Where is the NCT05160337 trial being conducted?
This trial is being conducted at Huningue, France.
Who is sponsoring the NCT05160337 clinical trial?
NCT05160337 is sponsored by Firalis SA. The principal investigator is Pierre Rohrlich, MD,Phd at Firalis SA. The trial plans to enroll 60 participants.